L. Hansen Carl - 07 Dec 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Tryn Stimart, attorney in fact
Issuer symbol
ABCL
Transactions as of
07 Dec 2021
Transactions value $
$0
Form type
4
Filing time
09 Dec 2021, 17:00:45 UTC
Previous filing
22 Nov 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABCL Common Shares 225K 07 Dec 2021 Direct
holding ABCL Common Shares 55.8M 07 Dec 2021 See Footnote F1
holding ABCL Common Shares 234K 07 Dec 2021 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share Option (right to buy) Award $0 +920K +18.43% $0.00 5.91M 07 Dec 2021 Common Shares 920K $14.55 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the Reporting Person.
F2 These shares are held by Hankla Family Trust (2019), of which the Reporting Person and his spouse are joint trustees. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
F3 The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date